Global Assistive Reproductive 麻豆原创 Research Report 2023

Publication ID:

PB510230779

Publication Date:

October 19, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Assisted reproductive technology (ART) are the medical procedures used for infertility treatment, in which eggs are surgically removed from the ovaries and are combined with the sperms in a laboratory.
The global Assistive Reproductive market is projected to reach US$ 38130 million in 2029, increasing from US$ 28150 million in 2022, with the CAGR of 4.6% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Assistive Reproductive market research.
The Assisted Reproductive Technology (ART) market is primarily driven by the increasing demand for fertility treatments and solutions to overcome infertility challenges. ART encompasses a range of medical procedures and technologies that aid individuals and couples in achieving pregnancy. The growing prevalence of infertility due to various factors such as age, lifestyle, and medical conditions, coupled with advancements in reproductive medicine and technology, contributes to market growth. Moreover, the demonstrated success of ART methods such as in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) in helping couples conceive further propels adoption. However, challenges include addressing ethical considerations, optimizing treatment protocols, and managing the emotional and psychological aspects of fertility treatments. Navigating legal regulations, ensuring affordability and accessibility, and providing comprehensive patient support are ongoing concerns. The market's success relies on continuous research in reproductive health, collaborations between fertility clinics and medical manufacturers, and comprehensive patient education on the benefits and potential challenges of using ART while addressing the evolving challenges associated with infertility treatment and family planning.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Assistive Reproductive market with multiple angles, which provides sufficient supports to readers鈥� strategy and decision making.
By Company
Cooper Surgical
Hamilton Thorne
FUJIFILM Irvine Scientific
Nidacon International
Vitrolife AB
Merck
INVO Bioscience
IVFtech
Gonagen Medikal
Cook Medical
CellCura
Segment by Type
In-vitro fertilization (IVF)
Artificial Insemination-Intrauterine Insemination (AI-IUI)
Frozen Embryo Replacement (FER)
Other
Segment by Application
Fertility Clinics
IVF Center
Hospital
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Assistive Reproductive report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. 麻豆原创 Opportunities and Challenges
Chapter 3: Companies鈥� Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies鈥� Outline
Chapter 12: 麻豆原创 Conclusions
Chapter 13: Research Methodology and Data Source

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Assistive Reproductive 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 In-vitro fertilization (IVF)
1.2.3 Artificial Insemination-Intrauterine Insemination (AI-IUI)
1.2.4 Frozen Embryo Replacement (FER)
1.2.5 Other
1.3 麻豆原创 by Application
1.3.1 Global Assistive Reproductive 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Fertility Clinics
1.3.3 IVF Center
1.3.4 Hospital
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Assistive Reproductive 麻豆原创 Perspective (2018-2029)
2.2 Assistive Reproductive Growth Trends by Region
2.2.1 Global Assistive Reproductive 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Assistive Reproductive Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Assistive Reproductive Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Assistive Reproductive 麻豆原创 Dynamics
2.3.1 Assistive Reproductive Industry Trends
2.3.2 Assistive Reproductive 麻豆原创 Drivers
2.3.3 Assistive Reproductive 麻豆原创 Challenges
2.3.4 Assistive Reproductive 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Assistive Reproductive Players by Revenue
3.1.1 Global Top Assistive Reproductive Players by Revenue (2018-2023)
3.1.2 Global Assistive Reproductive Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Assistive Reproductive 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Assistive Reproductive Revenue
3.4 Global Assistive Reproductive 麻豆原创 Concentration Ratio
3.4.1 Global Assistive Reproductive 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Assistive Reproductive Revenue in 2022
3.5 Assistive Reproductive Key Players Head office and Area Served
3.6 Key Players Assistive Reproductive Product Solution and Service
3.7 Date of Enter into Assistive Reproductive 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Assistive Reproductive Breakdown Data by Type
4.1 Global Assistive Reproductive Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Assistive Reproductive Forecasted 麻豆原创 Size by Type (2024-2029)
5 Assistive Reproductive Breakdown Data by Application
5.1 Global Assistive Reproductive Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Assistive Reproductive Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Assistive Reproductive 麻豆原创 Size (2018-2029)
6.2 North America Assistive Reproductive 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Assistive Reproductive 麻豆原创 Size by Country (2018-2023)
6.4 North America Assistive Reproductive 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Assistive Reproductive 麻豆原创 Size (2018-2029)
7.2 Europe Assistive Reproductive 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Assistive Reproductive 麻豆原创 Size by Country (2018-2023)
7.4 Europe Assistive Reproductive 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Assistive Reproductive 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Assistive Reproductive 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Assistive Reproductive 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Assistive Reproductive 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Assistive Reproductive 麻豆原创 Size (2018-2029)
9.2 Latin America Assistive Reproductive 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Assistive Reproductive 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Assistive Reproductive 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Assistive Reproductive 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Assistive Reproductive 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Assistive Reproductive 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Assistive Reproductive 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Cooper Surgical
11.1.1 Cooper Surgical Company Detail
11.1.2 Cooper Surgical Business Overview
11.1.3 Cooper Surgical Assistive Reproductive Introduction
11.1.4 Cooper Surgical Revenue in Assistive Reproductive Business (2018-2023)
11.1.5 Cooper Surgical Recent Development
11.2 Hamilton Thorne
11.2.1 Hamilton Thorne Company Detail
11.2.2 Hamilton Thorne Business Overview
11.2.3 Hamilton Thorne Assistive Reproductive Introduction
11.2.4 Hamilton Thorne Revenue in Assistive Reproductive Business (2018-2023)
11.2.5 Hamilton Thorne Recent Development
11.3 FUJIFILM Irvine Scientific
11.3.1 FUJIFILM Irvine Scientific Company Detail
11.3.2 FUJIFILM Irvine Scientific Business Overview
11.3.3 FUJIFILM Irvine Scientific Assistive Reproductive Introduction
11.3.4 FUJIFILM Irvine Scientific Revenue in Assistive Reproductive Business (2018-2023)
11.3.5 FUJIFILM Irvine Scientific Recent Development
11.4 Nidacon International
11.4.1 Nidacon International Company Detail
11.4.2 Nidacon International Business Overview
11.4.3 Nidacon International Assistive Reproductive Introduction
11.4.4 Nidacon International Revenue in Assistive Reproductive Business (2018-2023)
11.4.5 Nidacon International Recent Development
11.5 Vitrolife AB
11.5.1 Vitrolife AB Company Detail
11.5.2 Vitrolife AB Business Overview
11.5.3 Vitrolife AB Assistive Reproductive Introduction
11.5.4 Vitrolife AB Revenue in Assistive Reproductive Business (2018-2023)
11.5.5 Vitrolife AB Recent Development
11.6 Merck
11.6.1 Merck Company Detail
11.6.2 Merck Business Overview
11.6.3 Merck Assistive Reproductive Introduction
11.6.4 Merck Revenue in Assistive Reproductive Business (2018-2023)
11.6.5 Merck Recent Development
11.7 INVO Bioscience
11.7.1 INVO Bioscience Company Detail
11.7.2 INVO Bioscience Business Overview
11.7.3 INVO Bioscience Assistive Reproductive Introduction
11.7.4 INVO Bioscience Revenue in Assistive Reproductive Business (2018-2023)
11.7.5 INVO Bioscience Recent Development
11.8 IVFtech
11.8.1 IVFtech Company Detail
11.8.2 IVFtech Business Overview
11.8.3 IVFtech Assistive Reproductive Introduction
11.8.4 IVFtech Revenue in Assistive Reproductive Business (2018-2023)
11.8.5 IVFtech Recent Development
11.9 Gonagen Medikal
11.9.1 Gonagen Medikal Company Detail
11.9.2 Gonagen Medikal Business Overview
11.9.3 Gonagen Medikal Assistive Reproductive Introduction
11.9.4 Gonagen Medikal Revenue in Assistive Reproductive Business (2018-2023)
11.9.5 Gonagen Medikal Recent Development
11.10 Cook Medical
11.10.1 Cook Medical Company Detail
11.10.2 Cook Medical Business Overview
11.10.3 Cook Medical Assistive Reproductive Introduction
11.10.4 Cook Medical Revenue in Assistive Reproductive Business (2018-2023)
11.10.5 Cook Medical Recent Development
11.11 CellCura
11.11.1 CellCura Company Detail
11.11.2 CellCura Business Overview
11.11.3 CellCura Assistive Reproductive Introduction
11.11.4 CellCura Revenue in Assistive Reproductive Business (2018-2023)
11.11.5 CellCura Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Cooper Surgical
Hamilton Thorne
FUJIFILM Irvine Scientific
Nidacon International
Vitrolife AB
Merck
INVO Bioscience
IVFtech
Gonagen Medikal
Cook Medical
CellCura

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.